Loading view.
Fentanyl Crisis
Subcommittee Hearing
Lowering Unaffordable Costs: Examining Transparency And Competition In Health Care
Subcommittee Hearing
HHS FY24 Budget Request
Subcommittee Hearing
Animal Drug User Fee Reauthorization
Subcommittee Hearing
Federal Health, Primary Care Programs
Subcommittee Hearing
Health Care Cost Transparency and Competition
Subcommittee Hearing
Public Health Security Threat Preparedness
Subcommittee Hearing
Public Health Security Threat Preparedness
Subcommittee Hearing
Rare Disease Care Access and Research
Subcommittee Hearing
Drug Overdose Legislation
Subcommittee Hearing
Medicare Coverage Pathways
Subcommittee Hearing
Generic Drug Shortages
Subcommittee Hearing
Seniors’ Access to Innovative Health Care
Subcommittee Hearing
Medicare Proposals
Subcommittee Hearing
Access to Long-Term Care Services
Subcommittee Hearing
Artificial Intelligence in Health Care
Subcommittee Markup
Domestic Health Care Spending
Subcommittee Hearing
Legislation to Support Patients and Caregivers
Subcommittee Hearing
Rare Disease Legislation
Subcommittee Hearing
Diagnostic Test Regulation
Subcommittee Hearing
Telehealth Access
Subcommittee Hearing
Health Sector Cybersecurity
Subcommittee Hearing
FY25 HHS Budget Request
Subcommittee Hearing
Medicaid Access
Subcommittee Hearing
FDA Drugs, Biologics, and Devices Regulation
Subcommittee Hearing
Value-Based Care
Subcommittee Hearing
CDC Priorities and Public Trust
Subcommittee Hearing
FDA Human Foods and Tobacco Legislation
Subcommittee Hearing
FDA Human Foods and Tobacco Programs Oversight
Subcommittee Hearing
Emerging Illicit Drug Threats
Subcommittee Hearing
PBM Marketplace Reform
Subcommittee Hearing